Related Experiment Videos
Aspirin for cardiovascular disease prevention
1School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, WA. jhung@cyllene.uwa.edu.au
The Medical Journal of Australia
|July 30, 2003
Summary
Low-dose aspirin benefits patients with established coronary heart disease and those at high risk of cardiovascular events. However, potential bleeding risks necessitate careful consideration of individual health factors and lifestyle changes.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Coronary heart disease (CHD) and peripheral arterial disease (PAD) represent significant public health concerns.
- Aspirin is widely recognized for its antiplatelet effects, but its role in various clinical scenarios requires ongoing evaluation.
Purpose of the Study:
- To summarize the established benefits of aspirin in secondary prevention for patients with manifestations of coronary heart disease and peripheral arterial disease.
- To evaluate the role of low-dose aspirin in primary prevention for individuals at increased risk of cardiovascular events.
Main Methods:
- Review of existing literature and clinical guidelines on aspirin use in cardiovascular disease prevention.
- Analysis of the risk-benefit profile of aspirin, considering both efficacy and potential adverse effects, particularly bleeding.
Main Results:
- Aspirin demonstrates clear benefits in secondary prevention across diverse CHD and PAD patient groups, including those with myocardial infarction, angina, stroke, and peripheral arterial insufficiency.
- Low-dose aspirin (75-150 mg daily) can reduce cardiovascular risk in asymptomatic individuals with elevated risk (>1% annual risk), but this decision requires individualized assessment.
Conclusions:
- Aspirin is a cornerstone therapy for secondary prevention in cardiovascular and peripheral arterial diseases.
- Primary prevention with aspirin should be integrated into a comprehensive lifestyle modification program, with careful consideration of bleeding risks versus cardiovascular benefits.